US Stock MarketDetailed Quotes

MURA Mural Oncology

Watchlist
  • 4.180
  • +0.190+4.76%
Close Dec 2 16:00 ET
71.31MMarket Cap-463P/E (TTM)

About Mural Oncology Company

Mural Oncology Plc is a clinical-stage oncology company, which engages in the business of discovering and developing immunotherapies for patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.

Company Profile

SymbolMURA
Company NameMural Oncology
Listing DateNov 6, 2023
Founded2017
CEODr. Caroline Loew, PhD
MarketNASDAQ
Employees117
Fiscal Year Ends12-31
Address10 Earlsfort Terrace
CityDublin
ProvinceDublin
CountryIreland
Zip Code2
Phone353-1-905-8020
Websitehttp://www.muraloncology.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Caroline Loew, PhD
  • Chief Executive Officer and Director
  • 2.52M
  • Vicki L. Goodman
  • Chief Medical Officer
  • 705.58K
  • Maiken Keson-Brookes
  • Chief Legal Officer
  • --
  • Adam D. Cutler
  • Chief Financial Officer and Principal Accounting Officer
  • 743.18K
  • Scott T. Jackson, M.B.A.
  • Chairman of the Board
  • 65.97K
  • Benjamin J. Hickey, M.B.A.
  • Independent Director
  • 51.79K
  • Dr. Francis M. Cuss, F.R.C.P.,M.B.
  • Independent Director
  • 58.63K
  • Sachiyo Minegishi, M.B.A.
  • Independent Director
  • --
  • Dr. George S. Golumbeski, PhD
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data